KaloBios Sacks CEO Shkreli
This article was originally published in Scrip
KaloBios Pharmaceuticals Inc. has fired CEO Martin Shkreli following his arrest for securities fraud on Dec. 17, 2015. Shkreli has also resigned from the company's board of directors and stepped down as CEO of Turing Pharmaceuticals, Inc. KaloBios has not yet named an interim or replacement CEO.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.